Cargando…

A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

OBJECTIVE: Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Efficacy and safety have been evaluated in five Phase II/III studies, four of which met the pre-specified primary efficacy out...

Descripción completa

Detalles Bibliográficos
Autores principales: Gommoll, Carl P., Greenberg, William M., Chen, Changzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937636/
https://www.ncbi.nlm.nih.gov/pubmed/27536449
http://dx.doi.org/10.3109/21556660.2014.884505
_version_ 1782441742893580288
author Gommoll, Carl P.
Greenberg, William M.
Chen, Changzheng
author_facet Gommoll, Carl P.
Greenberg, William M.
Chen, Changzheng
author_sort Gommoll, Carl P.
collection PubMed
description OBJECTIVE: Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Efficacy and safety have been evaluated in five Phase II/III studies, four of which met the pre-specified primary efficacy outcome. Results of the negative trial (ClinicalTrials.gov NCT00969150) are reported here. METHODS: A Phase III randomized, double-blind, placebo-controlled trial comparing flexible-dose levomilnacipran ER 40–120 mg/day with placebo was conducted in outpatients with MDD. Patients met the DSM-IV-TR criteria for MDD, had a current episode of depression of at least 4 weeks’ duration, and a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥30. The study comprised a 1-week, single-blind, placebo lead-in, 8-week double-blind treatment, and a 2-week down-taper. The primary and secondary efficacy measures were change from baseline to Week 8 in MADRS and Sheehan Disability Scale (SDS) total scores, respectively, analyzed using a mixed-effects model for repeated measures approach. Safety outcomes included adverse events (AEs), laboratory and vital sign measures, the Columbia-Suicide Severity Rating Scale, and the Arizona Sexual Experiences Scale (ASEX). RESULTS: Three hundred and fifty-five patients received the study drug and had ≥1 post-baseline MADRS total score assessment (ITT Population); 81.9% of placebo and 77.1% of levomilnacipran ER patients completed the study. For levomilnacipran ER vs placebo, MADRS (−15.7 vs −14.2) and SDS (−8.8 vs −8.2) total score improvements, and rates of MADRS response (38.5% vs 34.8%) and remission (25.3% vs 23.8%) were numerically greater but differences were not statistically significant. Levomilnacipran ER was generally well tolerated. More levomilnacipran ER patients vs placebo reported AEs; the most common AEs for levomilnacipran ER were nausea (17%) and headache (16%). Mean changes in most safety measures were small and similar between groups. There were no meaningful differences in total ASEX scores between groups. LIMITATIONS: Short duration of treatment, inclusion and exclusion criteria, and lack of an active comparator. CONCLUSION: Numerical improvements for levomilnacipran ER vs placebo were detected in this study, but the differences were not statistically significant; levomilnacipran ER was generally well tolerated.
format Online
Article
Text
id pubmed-4937636
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49376362016-08-17 A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder Gommoll, Carl P. Greenberg, William M. Chen, Changzheng J Drug Assess Original Articles OBJECTIVE: Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Efficacy and safety have been evaluated in five Phase II/III studies, four of which met the pre-specified primary efficacy outcome. Results of the negative trial (ClinicalTrials.gov NCT00969150) are reported here. METHODS: A Phase III randomized, double-blind, placebo-controlled trial comparing flexible-dose levomilnacipran ER 40–120 mg/day with placebo was conducted in outpatients with MDD. Patients met the DSM-IV-TR criteria for MDD, had a current episode of depression of at least 4 weeks’ duration, and a Montgomery-Åsberg Depression Rating Scale (MADRS) total score ≥30. The study comprised a 1-week, single-blind, placebo lead-in, 8-week double-blind treatment, and a 2-week down-taper. The primary and secondary efficacy measures were change from baseline to Week 8 in MADRS and Sheehan Disability Scale (SDS) total scores, respectively, analyzed using a mixed-effects model for repeated measures approach. Safety outcomes included adverse events (AEs), laboratory and vital sign measures, the Columbia-Suicide Severity Rating Scale, and the Arizona Sexual Experiences Scale (ASEX). RESULTS: Three hundred and fifty-five patients received the study drug and had ≥1 post-baseline MADRS total score assessment (ITT Population); 81.9% of placebo and 77.1% of levomilnacipran ER patients completed the study. For levomilnacipran ER vs placebo, MADRS (−15.7 vs −14.2) and SDS (−8.8 vs −8.2) total score improvements, and rates of MADRS response (38.5% vs 34.8%) and remission (25.3% vs 23.8%) were numerically greater but differences were not statistically significant. Levomilnacipran ER was generally well tolerated. More levomilnacipran ER patients vs placebo reported AEs; the most common AEs for levomilnacipran ER were nausea (17%) and headache (16%). Mean changes in most safety measures were small and similar between groups. There were no meaningful differences in total ASEX scores between groups. LIMITATIONS: Short duration of treatment, inclusion and exclusion criteria, and lack of an active comparator. CONCLUSION: Numerical improvements for levomilnacipran ER vs placebo were detected in this study, but the differences were not statistically significant; levomilnacipran ER was generally well tolerated. Taylor & Francis 2014-01-16 /pmc/articles/PMC4937636/ /pubmed/27536449 http://dx.doi.org/10.3109/21556660.2014.884505 Text en © 2014 The Author(s). Published by Taylor & Francis http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Original Articles
Gommoll, Carl P.
Greenberg, William M.
Chen, Changzheng
A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title_full A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title_fullStr A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title_full_unstemmed A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title_short A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
title_sort randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran er (40–120 mg/day) in patients with major depressive disorder
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937636/
https://www.ncbi.nlm.nih.gov/pubmed/27536449
http://dx.doi.org/10.3109/21556660.2014.884505
work_keys_str_mv AT gommollcarlp arandomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder
AT greenbergwilliamm arandomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder
AT chenchangzheng arandomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder
AT gommollcarlp randomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder
AT greenbergwilliamm randomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder
AT chenchangzheng randomizeddoubleblindplacebocontrolledstudyofflexibledosesoflevomilnacipraner40120mgdayinpatientswithmajordepressivedisorder